Instanyl Sets New Standard In Management Of Breakthrough Cancer Pain
New data presented today, 11-Sep-2009, further demonstrate the efficacy of Instanyl in management of breakthrough cancer pain. The data which were presented at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC) are from a multinational, crossover trial comparing Instanyl with oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in patients with cancer.
Related Posts
Tags: breakthrough, cancer, instanyl, management, pain, sets, standard
This entry was posted on Sunday, September 13th, 2009 at 1:09 am and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.



